NephroGenex, Inc

Description

Treatment of end stage renal disease (ESRD) accounts for up to 15% of the entire health care budget in the United States, with annual costs estimated at $24 billion. In spite of the enormous socioeconomic burden, renal diseases are dramatically underserved by the pharmaceutical industry in contrast to cancer, cardiovascular disease, neurological diseases and diabetes. The recently determined polygenic etiology of the leading renal diseases and the related difficulty in identifying and validating drug targets and appropriate patient populations, are major hurdles for kidney disease drug development.

Companies nearby